Attached files

                                  EXHIBIT 99.1







CEL-SCI CORPORATION                                             NEWS

8229 Boone Boulevard, Suite 802                          COMPANY CONTACT:
Vienna, VA  22182.  USA                                  Gavin de Windt
Telephone (703) 506-9460                                 CEL-SCI Corporation
 www.cel-sci.com                                         (703) 506-9460

             CEL-SCI Corporation Announces Proposed Public Offering
                          of Common Stock and Warrants

Vienna, VA, December 18, 2013 - CEL-SCI Corporation (NYSE MKT: CVM), a
late-stage oncology company, today announced that it intends to offer and sell
common stock and warrants in an underwritten public offering. The offering is
subject to market conditions, and there can be no assurance as to whether or
when the offering may be completed.

Laidlaw & Company  (UK) Ltd.  is acting as sole  book-running  manager for the
offering.   Dawson  James  Securities,  Inc. is acting as  co-manager  for the
offering.

A shelf  registration  statement and  accompanying  base  prospectus on Form S-3
relating to the securities was filed with the Securities and Exchange Commission
and is effective.  A preliminary  prospectus supplement relating to the offering
has  been  filed  with  the  SEC  and is  available  on the  SEC's  web  site at
http://www.sec.gov.  Copies of the final prospectus  supplement  relating to the
offering, when available,  may be obtained from the offices of Laidlaw & Company
(UK) Ltd.,  546 Fifth  Avenue,  23rd  Floor,  New York,  NY,  10036,  telephone:
212-953-4900., or from the above-mentioned SEC website.

This press release shall not constitute an offer to sell or the  solicitation of
an  offer  to buy  these  securities,  nor  shall  there  be any  sale of  these
securities in any  jurisdiction in which such offer,  solicitation or sale would
be unlawful prior to the registration or qualification under the securities laws
of any such jurisdiction.

About CEL-SCI Corporation

CEL-SCI is  dedicated  to research and  development  directed at  improving  the
treatment  of cancer and other  diseases by  utilizing  the immune  system,  the
body's natural defense  system.  The lead  investigational  therapy is Multikine
(Leukocyte Interleukin,  Injection), currently being studied in a pivotal global
Phase  III  clinical   trial.   CEL-SCI  is  also   investigating   a  different
peptide-based  immunotherapy  (LEAPS-H1N1-DC)  as a possible  treatment for H1N1
hospitalized   patients  and  a  vaccine  (CEL-2000)  for  Rheumatoid  Arthritis
(currently in preclinical  testing)  using its LEAPS  technology  platform.  The
investigational  immunotherapy  LEAPS-H1N1-DC  treatment  involves  non-changing
regions of H1N1  Pandemic  Flu (See Journal of Clinical  Investigation  - J Clin
Invest. 2013; 123(7):2850-2861. doi: 10.1172/JCI67550) Avian Flu (H5N1), and the
Spanish  Flu,  as  CEL-SCI  scientists  are very  concerned  about the  possible
emergence of a new more virulent  hybrid virus through the  combination  of H1N1
and Avian Flu, or maybe  Spanish  Flu.  The Company  has  operations  in Vienna,
Virginia, and in/near Baltimore, Maryland.



*Multikine is the trademark that CEL-SCI has registered for this investigational
therapy,  and this  proprietary name is subject to FDA review in connection with
its future  anticipated  regulatory  submission for approval.  Multikine has not
been  licensed or approved for sale,  barter or exchange by the FDA or any other
regulatory  agency.  Similarly,  its safety or efficacy has not been established
for  any  use.  Moreover,  no  definitive  conclusions  can be  drawn  from  the
early-phase,   clinical-trials   data  involving  the  investigational   therapy
Multikine (Leukocyte Interleukin,  Injection). Further research is required, and
early-phase  clinical  trial  results must be confirmed in the  well-controlled,
Phase III clinical  trial of this  investigational  therapy that is currently in
progress.

Safe Harbor Statement

When used in this release,  the words "intends,"  "believes,"  "anticipated" and
"expects"  and similar  expressions  are  intended  to identify  forward-looking
statements.   Forward-looking   statements  include,  without  limitation,   the
company's  ability to complete the proposed  public offering of its common stock
and  warrants  described  above.  Such  statements  are  subject  to  risks  and
uncertainties  which could cause actual results to differ  materially from those
projected.  The Company  undertakes no obligation to publicly release the result
of any revision to these forward-looking statements which may be made to reflect
the events or  circumstances  after the date hereof or to reflect the occurrence
of unanticipated events.